The newly emerged variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) demonstrate resistance to presenttherapeutic antibodies as well as the capability to evade vaccination-elicited antibodies. JN...The newly emerged variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) demonstrate resistance to presenttherapeutic antibodies as well as the capability to evade vaccination-elicited antibodies. JN.1 sublineages were demonstrated as oneof the most immune-evasive variants, showing higher neutralization resistance compared to XBB.1.5. In this study, serum sampleswere collected from adult participants including those who had gone through the BA.5/BF.7, EG.5/HK.3 and XBB/JN.1 infectionwaves, characterized by different infection and vaccination histories. We evaluated the neutralization in these serum samples againstpseudoviruses of Omicron lineages. We further investigated humoral immune response of recombinant XBB vaccines againstOmicron variants and estimated the neutralization resistance of JN.1 sublineages, including KP.2 and KP.3. Our results showed thatsera from previous circulating Omicron subvariant breakthrough infections exhibited low neutralization against pseudoviruses ofOmicron lineages. The GMTs of 50% neutralization against all tested pseudoviruses were significantly elevated in sera fromindividuals who received WSK-V102C or WSK-V102D boosters. Importantly, the GMTs of 50% neutralization in serum samples fromindividuals 4 months after a WSK-V102D booster against XBB.1.5, JN.1, JN.1.13, KP.2 and KP.3 pseudoviruses were 3479, 1684, 1397,1247 and 1298, with 9.86-, 9.79-, 8.73-, 8.66- and 8.16-fold increase compared to those without booster, respectively, indicating thatboosting with XBB.1.5 subunit vaccines still induced strong antibody responses against JN.1 sublineages. However, JN.1 sublineages,including KP.2 and KP.3, revealed more than 2-fold decreases in neutralizing antibody titers compared to XBB.1.5, suggestingsignificantly enhanced neutralization evasion and the necessity of boosters based on JN.1, KP.2 or KP.3.展开更多
基金supported by the Young Scientists Fund of National Natural Science Foundation of China(No.82200018)National Natural Science Foundation of China(No.32400776)+1 种基金China Postdoctoral Science Foundation(No.2023T160458)the Project of the Science and Technology Department of Sichuan Province(No.2023NSFSC1655).
文摘The newly emerged variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) demonstrate resistance to presenttherapeutic antibodies as well as the capability to evade vaccination-elicited antibodies. JN.1 sublineages were demonstrated as oneof the most immune-evasive variants, showing higher neutralization resistance compared to XBB.1.5. In this study, serum sampleswere collected from adult participants including those who had gone through the BA.5/BF.7, EG.5/HK.3 and XBB/JN.1 infectionwaves, characterized by different infection and vaccination histories. We evaluated the neutralization in these serum samples againstpseudoviruses of Omicron lineages. We further investigated humoral immune response of recombinant XBB vaccines againstOmicron variants and estimated the neutralization resistance of JN.1 sublineages, including KP.2 and KP.3. Our results showed thatsera from previous circulating Omicron subvariant breakthrough infections exhibited low neutralization against pseudoviruses ofOmicron lineages. The GMTs of 50% neutralization against all tested pseudoviruses were significantly elevated in sera fromindividuals who received WSK-V102C or WSK-V102D boosters. Importantly, the GMTs of 50% neutralization in serum samples fromindividuals 4 months after a WSK-V102D booster against XBB.1.5, JN.1, JN.1.13, KP.2 and KP.3 pseudoviruses were 3479, 1684, 1397,1247 and 1298, with 9.86-, 9.79-, 8.73-, 8.66- and 8.16-fold increase compared to those without booster, respectively, indicating thatboosting with XBB.1.5 subunit vaccines still induced strong antibody responses against JN.1 sublineages. However, JN.1 sublineages,including KP.2 and KP.3, revealed more than 2-fold decreases in neutralizing antibody titers compared to XBB.1.5, suggestingsignificantly enhanced neutralization evasion and the necessity of boosters based on JN.1, KP.2 or KP.3.
